×
About 4,590 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  1,106 results

Variable and Severe Phenotypic Expression of the "Lebanese Allele" in Two Sisters with ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312315
Vascular Health and Risk Management; Chahine J, Kreykes S et. al.

Jul 30th, 2021 - The "Lebanese allele" {LDLR c.2043 C>A (p.cys681X)} is a nonsense mutation in the low-density lipoprotein receptor (LDLR) gene that results in a truncated non-functioning LDLR protein. We report two sisters of Lebanese descent who presented with f...

Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients.
https://doi.org/10.18632/aging.203320
Aging Tung H, Lin HJ et. al.

Jul 28th, 2021 - Familial hypercholesterolemia (FH) is a common genetic disorder characterized by a lifelong elevated low-density lipoprotein cholesterol (LDL-C) level. The relationship between FH and ischemic stroke is still controversial. We enrolled ischemic st...

Alirocumab treatment and neurocognitive function according to the CANTAB scale in patie...
https://doi.org/10.1016/j.atherosclerosis.2021.06.913
Atherosclerosis Janik MJ, Urbach DV et. al.

Jul 25th, 2021 - Trials of the fully human monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) alirocumab in hypercholesterolemia demonstrated substantial low-density lipoprotein cholesterol (LDL-C) lowering, reduction in cardiovasc...

Genetic spectrum of Familial Hypercholesterolemia and correlations with clinical expres...
https://doi.org/10.1111/cge.14036
Clinical Genetics; Di Taranto MD, Giacobbe C et. al.

Jul 24th, 2021 - Familial Hypercholesterolemia (FH) is the most common genetic disease caused by variants in LDLR, APOB, PCSK9 genes; it is characterized by high levels of LDL-cholesterol and premature cardiovascular disease. We aim to perform a retrospective anal...

see more →

Guidelines  2 results

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 18th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

see more →

Drugs  356 results see all →

Clinicaltrials.gov  65 results

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT03399786

Apr 30th, 2020 - The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial hypercholesterolemia (H...

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
https://clinicaltrials.gov/ct2/show/NCT00001204

Feb 24th, 2020 - Familial hypercholesterolemia is an autosomal co-dominant disorder resulting in abnormal LDL receptor function, profoundly elevated concentrations of low density lipoproteins, accelerated atherosclerosis and death by early adulthood. This disease ...

Long Term Safety Study of PRALUENT
https://clinicaltrials.gov/ct2/show/NCT03694197

Feb 7th, 2020 - The primary objective of the study is to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) patients at high or very high cardiovascular risk w...

Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia
https://clinicaltrials.gov/ct2/show/NCT03234127

Oct 9th, 2019 - The objective of the SAFIR study is to perform non-invasive coronary vascular phenotyping of familial hypercholesterolemia (FH) families by performing a coronary calcium score and then to detect protective genetic factors in patients who do not ha...

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
https://clinicaltrials.gov/ct2/show/NCT03397121

Sep 17th, 2019 - This is a Phase III, placebo-controlled, double-blind, randomized study in participants with HeFH and elevated LDL-C to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) injection(s) of inclisiran. The study will be multicenter ...

see more →

News  305 results

Study Sheds Light on LDL-C Trajectories in Childhood, Supports Screening Advice
https://www.medscape.com/viewarticle/955032

Jul 21st, 2021 - NEW YORK (Reuters Health) - New data from the International Childhood Cardiovascular Cohort (i3C) consortium shed light on trajectories of low-density lipoprotein cholesterol (LDL-C) in childhood and on the possible prevalence of heterozygous fami...

Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement
https://www.medscape.com/viewarticle/953408

Jun 18th, 2021 - Patients with familial hypercholesterolemia (FH), particularly those with heterozygous FH, see their low-density-lipoprotein (LDL) cholesterol levels slashed with evolocumab (Repatha) and maintained out to 2 years, suggests data from the HEYMANS r...

Limited-Variant Screening Tests Often Miss Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/952069

May 31st, 2021 - NEW YORK (Reuters Health) - Two-thirds of cases of familial hypercholesterolemia (FH) would be missed by relying on array-based genetic tests that screen for only a limited number of variants, according to a new study. "Negative findings on a limi...

An Expert's Guide to Managing Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/948546

Apr 21st, 2021 - This transcript has been edited for clarity. Hi. I'm Seth Baum, a preventive cardiologist and clinical lipidologist in Boca Raton, Florida. I'm also the past president of the American Society for Preventive Cardiology and on the faculty at the Flo...

An Expert's Guide to Managing Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/948546?src=sapfe

Apr 21st, 2021 - This transcript has been edited for clarity. Hi. I'm Seth Baum, a preventive cardiologist and clinical lipidologist in Boca Raton, Florida. I'm also the past president of the American Society for Preventive Cardiology and on the faculty at the Flo...

see more →

Patient Education  2 results see all →